Greek drugmakers welcome government move on drug re-pricing

26 July 2010

The Greek pharmaceutical trade group the SFEE says it welcomes the government's decision to finally proceed with the re-pricing of all medicinal products by implementing article 14 of Law 3840/March 2010.

The Pricing Committee will validate the new prices in a meeting scheduled for August 19. The SFEE highlights once again, its willingness to provide additional data or any kind of support, should the Committee require it, in order to issue the new Price Bulletin.

Earlier this year, the Greek government introduced draconian measures to curb budget deficits including vicious price cuts for pharmaceutical products (The Pharma Letter May 6). Under this, the weighted average of the price reductions introduced was 21.5%, aimed at yielding annual savings of an estimated 1.9 billion euros ($2.46 billion).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical